Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.

[1]  H. Sampson,et al.  Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. , 2011, The Journal of allergy and clinical immunology.

[2]  O. Ogawa,et al.  Differential control of allo-antigen-specific regulatory T cells and effector T cells by anti-CD4 and other agents in establishing transplantation tolerance. , 2009, International immunology.

[3]  M. Kleinewietfeld,et al.  CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. , 2009, Blood.

[4]  T. Abraham,et al.  Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3 , 2008, European journal of immunology.

[5]  C. Akdis,et al.  In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposure , 2008, The Journal of experimental medicine.

[6]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[7]  Irma Joosten,et al.  Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. , 2008, Blood.

[8]  Erin L. Schenk,et al.  Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo1 , 2008, The Journal of Immunology.

[9]  Shimon Sakaguchi,et al.  Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation , 2008, Proceedings of the National Academy of Sciences.

[10]  K. Shokat,et al.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR , 2008, Proceedings of the National Academy of Sciences.

[11]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[12]  C. June,et al.  Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1 , 2008, The Journal of Immunology.

[13]  D. Vignali.  How many mechanisms do regulatory T cells need? , 2008, European journal of immunology.

[14]  C. Benoist,et al.  The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells , 2008, The Journal of experimental medicine.

[15]  Yan Li,et al.  Essential roles of TGF‐β in anti‐CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells , 2008, Journal of leukocyte biology.

[16]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[17]  B. Bohle,et al.  Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. , 2007, The Journal of allergy and clinical immunology.

[18]  Y. Belkaid,et al.  Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid , 2007, The Journal of experimental medicine.

[19]  R. Noelle,et al.  All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation , 2007, The Journal of experimental medicine.

[20]  E. Shevach,et al.  Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. , 2007, Blood.

[21]  Hilde Cheroutre,et al.  Reciprocal TH17 and Regulatory T Cell Differentiation Mediated by Retinoic Acid , 2007, Science.

[22]  J. Bluestone,et al.  Adaptive TGF-β-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment , 2007, Proceedings of the National Academy of Sciences.

[23]  M. Roncarolo,et al.  Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. , 2007, International immunology.

[24]  Shimon Sakaguchi,et al.  Natural regulatory T cells: mechanisms of suppression. , 2007, Trends in molecular medicine.

[25]  M. Yanai,et al.  Functional Analysis of Birch Pollen Allergen Bet v 1-Specific Regulatory T Cells1 , 2007, The Journal of Immunology.

[26]  T. Whiteside,et al.  Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1 , 2007, The Journal of Immunology.

[27]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[28]  Geraint T. Williams,et al.  CD4+CD25+FOXP3+ Regulatory T Cells Suppress Anti-Tumor Immune Responses in Patients with Colorectal Cancer , 2006, PloS one.

[29]  M. Battaglia,et al.  Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.

[30]  R. Andreesen,et al.  Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. , 2006, Blood.

[31]  R. Geffers,et al.  Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. , 2006, Blood.

[32]  S. Wahl,et al.  TGF‐β: a mobile purveyor of immune privilege , 2006 .

[33]  C. Akdis,et al.  Immunological mechanisms of allergen-specific immunotherapy , 2006, Nature Reviews Immunology.

[34]  P. Kerkhof.  Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. , 2006 .

[35]  Katharina Fleischhauer,et al.  Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans , 2006, Immunological reviews.

[36]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[37]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[38]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[39]  S. Sakaguchi,et al.  Regulatory T cells in immune surveillance and treatment of cancer. , 2006, Seminars in cancer biology.

[40]  A. Rudensky,et al.  An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires , 2006, Nature Immunology.

[41]  T. Chatila,et al.  Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. , 2005, The Journal of allergy and clinical immunology.

[42]  B. Bisikirska,et al.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.

[43]  H. Mcdevitt,et al.  Expansion of Functional Endogenous Antigen-Specific CD4+CD25+ Regulatory T Cells from Nonobese Diabetic Mice1 , 2005, The Journal of Immunology.

[44]  D. Valmori,et al.  A peripheral circulating compartment of natural naive CD4 Tregs. , 2005, The Journal of clinical investigation.

[45]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[46]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[47]  J. Bluestone,et al.  Treatment with Nonmitogenic Anti-CD3 Monoclonal Antibody Induces CD4+ T Cell Unresponsiveness and Functional Reversal of Established Experimental Autoimmune Encephalomyelitis1 , 2005, The Journal of Immunology.

[48]  T. Nomura,et al.  Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. , 2004, International immunology.

[49]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[50]  H. von Boehmer,et al.  In Vivo Instruction of Suppressor Commitment in Naive T Cells , 2004, The Journal of experimental medicine.

[51]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[52]  D. Klatzmann,et al.  Continuous Activation of Autoreactive CD4+ CD25+ Regulatory T Cells in the Steady State , 2003, The Journal of experimental medicine.

[53]  Marek Jutel,et al.  IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy , 2003, European journal of immunology.

[54]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[55]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[56]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[57]  T. Sasazuki,et al.  Thymic generation and selection of CD25+CD4+ regulatory T cells: implications of their broad repertoire and high self-reactivity for the maintenance of immunological self-tolerance. , 2003, Novartis Foundation symposium.

[58]  D. Harlan,et al.  Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. , 2002, The New England journal of medicine.

[59]  R. Lechler,et al.  Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. , 2001, Blood.

[60]  J. Camardo,et al.  Rapamycin: clinical results and future opportunities. , 2001, Transplantation.

[61]  H. Weiner,et al.  Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.

[62]  G. Freeman,et al.  CD4+CD25high Regulatory Cells in Human Peripheral Blood1 , 2001, The Journal of Immunology.

[63]  G. Schuler,et al.  Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.

[64]  M. Roncarolo,et al.  Human Cd25+Cd4+ T Regulatory Cells Suppress Naive and Memory T Cell Proliferation and Can Be Expanded in Vitro without Loss of Function , 2001, The Journal of experimental medicine.

[65]  A. Enk,et al.  Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.

[66]  M. Salmon,et al.  Human anergic/suppressive CD4+CD25+ T cells: a highly differentiated and apoptosis‐prone population , 2001, European journal of immunology.

[67]  A. Naji,et al.  Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide , 2001, Nature Immunology.

[68]  H. Ochs,et al.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 , 2001, Nature Genetics.

[69]  J. Casanova,et al.  X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy , 2001, Nature Genetics.

[70]  D. Galas,et al.  Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse , 2001, Nature Genetics.

[71]  D. Mason,et al.  The third function of the thymus. , 2000, Immunology today.

[72]  S. Durham,et al.  Allergen immunotherapy: does it work and, if so, how and for how long? , 2000, Thorax.

[73]  F. Otsuka,et al.  Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. , 1999, Journal of immunology.

[74]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[75]  Ethan M. Shevach,et al.  CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production , 1998, The Journal of experimental medicine.

[76]  J. Bluestone,et al.  Nonmitogenic Anti-CD3 Monoclonal Antibodies Deliver a Partial T Cell Receptor Signal and Induce Clonal Anergy , 1997, The Journal of experimental medicine.

[77]  L. Chatenoud,et al.  Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.